Following a report from Bloomberg yesterday that Spectrum Pharmaceuticals is exploring options including a sale of the business amid takeover interest from other drugmakers, B. RIley FBR analyst David Buck told investors in a research note that while he has no confirmation of any takeover interest or sale process, he sees the report as "plausible." Buck, who reiterated a Buy rating, says that he continues to see his $26 per share target based on DCF and 2022E earnings power as "reasonable." Aide from any actual news on a potential transaction or sales process that gets confirmed, he expects further news flow on pipeline drug Rolontis, including a June 29 Spectrum-sponsored conference call and an expected presentation of additional poziotinib data at the World Lung Conference.